Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
3 Dividend Stocks That Should Pay You the Rest of Your Life
09:00am, Saturday, 18'th Feb 2023
Each of these companies can provide income investors with growing, market-beating passive income.
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
07:02am, Friday, 17'th Feb 2023
A new study published in Science Translational Medicine could introduce a profitable opportunity for makers of seizure drug medications. The discovery has immense medical implications, of course, but
Is This the Start of a Nightmare for AbbVie Stock?
09:10am, Thursday, 16'th Feb 2023
With a competitor set to devour market share, stormy waters might be ahead.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
3 Defensive Growth Stocks to Load Up on in Q1
03:49pm, Wednesday, 15'th Feb 2023
In this rather uncertain market, the search for defensive growth stocks is picking up. Indeed, this category of high-quality companies with steady cash flows and growing dividend distributions are so
4 Factor Dividend Growth Portfolio - January 2023 Update
06:48pm, Tuesday, 14'th Feb 2023
The 4 factor dividend growth portfolio was launched on November 1st, 2022, and is thus far off to a great start. The portfolio lost by 11 bps to the S&P 500 Total Return during the month of January.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Tuesday, 14'th Feb 2023
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 of the BEST Dividend Growth Stocks
09:07am, Tuesday, 14'th Feb 2023
All three of these companies have consistently increased their dividends at a fast pace.
Better Buy: Johnson & Johnson or AbbVie?
08:26am, Tuesday, 14'th Feb 2023
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.
The 7 Most Undervalued Dividend Aristocrats to Buy
05:42pm, Monday, 13'th Feb 2023
If there's anything better than having at least some exposure to passive income-providing enterprises, it's loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[
AbbVie Has a Mixed Outlook After Mixed Earnings
07:00am, Monday, 13'th Feb 2023
AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in ligh
Dividend Champion, Contender, And Challenger Highlights: Week Of February 12
03:22am, Sunday, 12'th Feb 2023
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
The Dividend Aristocrats Ranked By Quality Scores
09:30am, Saturday, 11'th Feb 2023
The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Arist
How This Income Method Could Lead To Financial Freedom
09:00am, Saturday, 11'th Feb 2023
We will go over our thesis as to how a diversified income method with low volatility could make you financially independent. We regularly write about multi-basket income strategies with an in-built he
Here's Exactly How AbbVie Stock Can Beat the Market In 2023
06:00am, Saturday, 11'th Feb 2023
Don't think the challenges for Humira doom AbbVie to a sub-par stock performance this year.
